Spots Global Cancer Trial Database for neurofibromatosis type 1
Every month we try and update this database with for neurofibromatosis type 1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Spinal Abnormalities in Neurofibromatosis Type 1 (NF1) | NCT00844129 | Neurofibromatos... | 6 Years - 9 Years | University of Utah | ||
| How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem | NCT01626846 | Neurofibromatos... | 14 Years - 17 Years | John Jay High School | ||
| Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma | NCT02839720 | Cutaneous Neuro... Neurofibromatos... Optic Nerve Gli... | Laboratory Biom... Selumetinib Sul... | 18 Years - | National Cancer Institute (NCI) | |
| Eligibility Screening for a NCI Pediatric Oncology Branch Research Study | NCT00026780 | Ewing Sarcoma Osteosarcoma Neuroblastoma Acute Lymphobla... Neurofibromatos... | - 35 Years | National Institutes of Health Clinical Center (CC) | ||
| Natural History Study of Patients With Neurofibromatosis Type I | NCT00924196 | Neurofibromatos... Malignant Perip... Plexiform Neuro... Optic Glioma Neurofibroma | 4 Weeks - | National Institutes of Health Clinical Center (CC) | ||
| Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1. | NCT02078401 | Neurofibromatos... | - 18 Years | Universitaire Ziekenhuizen KU Leuven | ||
| DPCP to Treat Cutaneous Neurofibromas Associated With NF1 | NCT05438290 | Cutaneous Neuro... | DPCP | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I | NCT00684398 | Neurofibromatos... Von Recklinghau... NF1 | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Natural History Study of Cutaneous Neurofibromas in People With NF1 | NCT05581511 | Neurofibromatos... Neurofibromatos... Neurofibromatos... Cutaneous Neuro... | Evaluation of t... | 1 Year - 100 Years | Johns Hopkins University | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Feasibility and Clinically Application of Magnetic Resonance Fingerprinting | NCT02387840 | Neurofibromatos... Brain Tumor Glioma | Magnetic Resona... Magnetic Resona... | - 35 Years | Case Comprehensive Cancer Center | |
| FARD (RaDiCo Cohort) (RaDiCo-FARD) | NCT05954416 | Inherited Epide... Ichthyosis Ectodermal Dysp... Incontinentia P... Neurofibromatos... Albinism Pemphigus Mucous Membrane... Palmoplantar Ke... | - | Institut National de la Santé Et de la Recherche Médicale, France | ||
| DPCP to Treat Cutaneous Neurofibromas Associated With NF1 | NCT05438290 | Cutaneous Neuro... | DPCP | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas | NCT03231306 | Neurofibromatos... Plexiform Neuro... | Binimetinib | 1 Year - | University of Alabama at Birmingham | |
| Reading Disability in Children With NF1 | NCT02397967 | Neurofibromatos... | Neuropsychologi... | 8 Years - 12 Years | University Hospital, Toulouse | |
| Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas | NCT01412892 | Neurofibromatos... Plexiform Neuro... Neurofibromatos... | RAD001: Everoli... | 18 Years - 60 Years | Assistance Publique - Hôpitaux de Paris | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs | NCT01218152 | Neurofibromatos... | - | KU Leuven | ||
| Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma | NCT00589784 | CNS Cancer Meningioma Intracranial He... Hemangioblastom... Neurofibromatos... | Sunitinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) | NCT00352599 | Neurofibromatos... | Lovastatin Lovastatin placebo pill | 10 Years - 50 Years | University of California, Los Angeles | |
| Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1 | NCT05238909 | Neurofibromatos... NF1 Neurofibromatos... | - | Ann & Robert H Lurie Children's Hospital of Chicago | ||
| PASS of Paediatric Patients Initiating Selumetinib | NCT05388370 | Neurofibromatos... | 3 Years - 17 Years | AstraZeneca | ||
| Natural History Study of Patients With Neurofibromatosis Type I | NCT00924196 | Neurofibromatos... Malignant Perip... Plexiform Neuro... Optic Glioma Neurofibroma | 4 Weeks - | National Institutes of Health Clinical Center (CC) | ||
| A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma | NCT03871257 | Low Grade Gliom... Neurofibromatos... Visual Pathway ... | Carboplatin Magnetic Resona... Quality-of-Life... Questionnaire A... Selumetinib Sul... Vincristine Sul... | 2 Years - 21 Years | National Cancer Institute (NCI) | |
| Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma | NCT01553149 | Neurofibromatos... Recurrent Child... Recurrent Child... | Lenalidomide Pharmacological... | - 21 Years | National Cancer Institute (NCI) | |
| Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach. | NCT02777775 | Cutaneous Neuro... Neurofibromatos... Plexiform Neuro... | Skin Biopsy | 18 Years - | Spectrum Health Hospitals | |
| Multi-center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients | NCT00667836 | Neurofibromatos... | 3 Years - 18 Years | Shriners Hospitals for Children | ||
| Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas | NCT00030264 | Neurofibromatos... Precancerous Co... | Methotrexate Vinblastine | - 25 Years | Children's Hospital of Philadelphia | |
| Spinal Abnormalities in Neurofibromatosis Type 1 (NF1) | NCT00844129 | Neurofibromatos... | 6 Years - 9 Years | University of Utah | ||
| Interventions for Reading Disabilities in NF1 | NCT02964884 | Neurofibromatos... Learning Disabi... Reading Disabil... NF1 | Lovastatin reading tutorin... Placebo Oral Ta... Other Academic ... | 8 Years - 20 Years | Vanderbilt University | |
| Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 | NCT02944032 | Neurofibromatos... | CogmedRM Mobymax | 8 Years - 16 Years | Children's National Research Institute | |
| Neurofibromatosis Type 1 Patient Registry | NCT01410006 | Neurofibromatos... | - | Washington University School of Medicine | ||
| A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 | NCT00853580 | Neurofibromatos... | Lovastatin ™ placebo | 8 Years - 15 Years | University of Alabama at Birmingham | |
| MicroRNAs in Patients With Neurofibromatosis Type 1 | NCT01595139 | Glioma Neurofibromatos... | 2 Years - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | ||
| Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | NCT02415153 | Neurofibromatos... Recurrent Child... Recurrent Child... Recurrent Prima... Refractory Prim... | Laboratory Biom... Pharmacological... Pomalidomide | 3 Years - 20 Years | National Cancer Institute (NCI) | |
| A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 | NCT00853580 | Neurofibromatos... | Lovastatin ™ placebo | 8 Years - 15 Years | University of Alabama at Birmingham | |
| A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas | NCT00634270 | Neurofibromatos... | Sirolimus | 3 Years - 75 Years | University of Alabama at Birmingham | |
| Frameshift Peptides of Children With NF1 | NCT04212351 | Neurofibromatos... | Frameshift Arra... | 1 Day - 30 Years | Children's National Research Institute | |
| Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1 | NCT01058330 | Neurofibromatos... | Plyometric trai... | 4 Years - 19 Years | Shriners Hospitals for Children | |
| Neurofibromatosis Type 1 Brain Tumor Genetic Risk | NCT01707836 | Neurofibromatos... Pediatric Brain... | - 18 Years | Washington University School of Medicine | ||
| Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas | NCT04924608 | Neurofibromatos... Plexiform Neuro... | Selumetinib Placebo | 18 Years - | AstraZeneca | |
| Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas | NCT00053937 | Neurofibromatos... Precancerous Co... | pirfenidone | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas | NCT00021541 | Neurofibroma, P... Neurofibromatos... | tipifarnib placebo | 3 Years - 25 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) | NCT04590235 | Neurofibromatos... Neurofibroma Pl... | Selumetinib | 3 Years - 99 Years | AstraZeneca | |
| Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma | NCT01553149 | Neurofibromatos... Recurrent Child... Recurrent Child... | Lenalidomide Pharmacological... | - 21 Years | National Cancer Institute (NCI) | |
| A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 | NCT00853580 | Neurofibromatos... | Lovastatin ™ placebo | 8 Years - 15 Years | University of Alabama at Birmingham | |
| A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas | NCT00634270 | Neurofibromatos... | Sirolimus | 3 Years - 75 Years | University of Alabama at Birmingham | |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | NCT01362803 | Neurofibromatos... Neurofibromatos... NF1 Neurofibroma, P... | AZD6244 | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain | NCT02471339 | Neurofibromatos... Plexiform Neuro... | Acceptance and ... | 16 Years - 59 Years | National Institutes of Health Clinical Center (CC) | |
| US Selumetinib Registry | NCT05683678 | Neurofibromatos... Plexiform Neuro... | 2 Years - 18 Years | Alexion Pharmaceuticals, Inc. | ||
| Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II | NCT02728388 | NEUROFIBROMATOS... | aminolevulinic ... | 14 Years - 30 Years | Medical College of Wisconsin | |
| Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients | NCT01218139 | Neurofibromatos... | - | KU Leuven | ||
| Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors | NCT00304083 | Neurofibromatos... Sarcoma | filgrastim doxorubicin hyd... etoposide ifosfamide conventional su... radiation thera... | - | Sarcoma Alliance for Research through Collaboration | |
| Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children | NCT03518710 | Neurofibromatos... | Neuropsychologi... Evaluation of t... | 7 Years - 9 Years | University Hospital, Toulouse | |
| How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem | NCT01626846 | Neurofibromatos... | 14 Years - 17 Years | John Jay High School | ||
| Selumetinib Paediatric NF1 Japan Study | NCT04495127 | Neurofibromatos... | Selumetinib | 3 Years - 18 Years | AstraZeneca | |
| Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas | NCT01125046 | Acoustic Schwan... Adult Anaplasti... Adult Ependymom... Adult Grade I M... Adult Grade II ... Adult Meningeal... Adult Papillary... Neurofibromatos... Neurofibromatos... Recurrent Adult... | bevacizumab | 18 Years - | Northwestern University | |
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | NCT00727233 | Neurofibromatos... Plexiform Neuro... | Nexavar (BAY 43... Toxicity, Pharm... Pharmacodynamic... Radiographic Ev... QOL assessment,... Bony Toxicity | 3 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients | NCT01218139 | Neurofibromatos... | - | KU Leuven | ||
| Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery | NCT02700230 | Metastatic Mali... Neurofibromatos... Recurrent Malig... | Computed Tomogr... Laboratory Biom... Oncolytic Measl... Quality-of-Life... Single Photon E... Magnetic Resona... Ultrasound Imag... Biospecimen Col... Biopsy Questionnaire A... | 18 Years - | Mayo Clinic | |
| Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma | NCT02839720 | Cutaneous Neuro... Neurofibromatos... Optic Nerve Gli... | Laboratory Biom... Selumetinib Sul... | 18 Years - | National Cancer Institute (NCI) | |
| AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine | NCT00326872 | Neurofibromatos... Plexiform Neuro... Spinal Cord Neu... | Cediranib Malea... | 18 Years - | National Cancer Institute (NCI) | |
| Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study | NCT05825365 | Neurofibromatos... Plexiform Neuro... Post-operative | Selumetinib Placebo | 3 Years - 18 Years | AstraZeneca | |
| Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 | NCT00314119 | Neurofibromatos... Neurofibroma | 20 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1 | NCT00865644 | Neurofibromatos... Cutaneous Neuro... | Imiquimod 5% Cr... | 18 Years - | Massachusetts General Hospital | |
| Eligibility Screening for a NCI Pediatric Oncology Branch Research Study | NCT00026780 | Ewing Sarcoma Osteosarcoma Neuroblastoma Acute Lymphobla... Neurofibromatos... | - 35 Years | National Institutes of Health Clinical Center (CC) | ||
| PASS of Paediatric Patients Initiating Selumetinib | NCT05388370 | Neurofibromatos... | 3 Years - 17 Years | AstraZeneca | ||
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | NCT01362803 | Neurofibromatos... Neurofibromatos... NF1 Neurofibroma, P... | AZD6244 | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain | NCT02471339 | Neurofibromatos... Plexiform Neuro... | Acceptance and ... | 16 Years - 59 Years | National Institutes of Health Clinical Center (CC) | |
| Effect of Lamotrigine on Cognition in NF1 | NCT02256124 | Neurofibromatos... | Lamotrigine Placebo | 12 Years - 18 Years | Erasmus Medical Center | |
| Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas | NCT01125046 | Acoustic Schwan... Adult Anaplasti... Adult Ependymom... Adult Grade I M... Adult Grade II ... Adult Meningeal... Adult Papillary... Neurofibromatos... Neurofibromatos... Recurrent Adult... | bevacizumab | 18 Years - | Northwestern University | |
| NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate | NCT00169611 | Neurofibromatos... | methylphenidate | 7 Years - 12 Years | Hospices Civils de Lyon | |
| Neurofibromatosis Type 1 Brain Tumor Genetic Risk | NCT01707836 | Neurofibromatos... Pediatric Brain... | - 18 Years | Washington University School of Medicine | ||
| Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas | NCT01412892 | Neurofibromatos... Plexiform Neuro... Neurofibromatos... | RAD001: Everoli... | 18 Years - 60 Years | Assistance Publique - Hôpitaux de Paris | |
| Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1) | NCT00111384 | Neurofibromatos... Legius Syndrome | 2 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Function of the Pigment Epithelium in Patients With Type 1 Neurofibromatosis | NCT04153344 | Neurofibromatos... | Electro-oculogr... Full-field elec... | 7 Years - | Assistance Publique - Hôpitaux de Paris | |
| Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas | NCT04730583 | Cutaneous Neuro... | Kybella 1064nm laser 755nm Alexandri... | 18 Years - 85 Years | Massachusetts General Hospital | |
| Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence | NCT04763109 | Neurofibromatos... | Whole-body Magn... | 5 Years - 17 Years | Cedars-Sinai Medical Center | |
| US Selumetinib Registry | NCT05683678 | Neurofibromatos... Plexiform Neuro... | 2 Years - 18 Years | Alexion Pharmaceuticals, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
